 |
 |
Program Schedule
- Thursday, November 7, 2002
- Friday, November 8, 2002
- Saturday, November 9, 2002
- Sunday, November 10, 2002
| Saturday, November 9, 2002 | ||
| 7:00 am-6:00 pm | Registration Open | |
| 7:00 am-8:00 am | Continental Breakfast in the Exhibit Hall | |
| 8:00 am-8:05 am | Keynote
Address Introduction Robert O. Dillman, MD Hoag Cancer Center |
|
| 8:05 am-9:00 am | Keynote
Address Targeting Genes to the Neovasculature David A. Cheresh, PhD The Scripps Research Institute |
|
| 9:00 am-9:15 am | Refreshment Break | |
| 9:15 am-11:30 am | Joint Session: Angiogenesis | |
|
Co-Chairs: Lee S. Rosen,
MD |
||
| 9:15 am-9:45 am | Antiangiogenic
Metronomic Chemotherapy: Preclinical and Clinical Aspects Robert Kerbel, PhD Sunnybrook Health Science Center |
|
| 9:45 am-10:15 am | Lee
M. Ellis, MD MD Anderson Cancer Center |
|
| 10:15 am-10:45 am | Lee
S. Rosen, MD Cancer Institute Medical Group |
|
| 10:45 am-11:00 am | Requisite
Role of p38 MAPK in Mural Cell during Angiogenesis Wen-Hui Zhu, MD, PhD University of Washington |
|
| 11:00 am-11:15 am | Therapeutic
Effects of Anti-flt-1 and Anti-kdr Ribozymes Against Primary &
Metastatic 4T1 Murine Mammary Carcinoma Julian A. Kim, MD The Cleveland Clinic Foundation |
|
| 11:15 am-11:30 am | Functional
CT Measurement of Tumor Angiogenesis Satoshi Kobayashi, MD MD Anderson Cancer Center |
|
| 11:30 am-1:00 pm | Poster
Session (authors must be present) Box lunches will be available in the Scripps Hallway |
|
| 1:00 pm-2:30 pm |  Presidential
SessionSponsored by a grant from |
|
| Chair:
Robert O. Dillman, MD Hoag Cancer Center |
||
| 1:00 pm-1:15 pm | Differential
Cytokine Expression by Mature and Immature Dendritic Cells Dirk Nagorsen, MD National Institutes of Health |
|
| 1:15 pm-1:30 pm | Changes
in Plasma Levels of Pro-Angiogenic Factors in Patients Receiving Interleukin-12
and Interferon-alpha Jennifer Biber Ohio State University |
|
| 1:30 pm-1:45 pm | Fixed
Tumor Cell Vaccines Containing a Cytokine-Slow-Release Material-Effects
on Mouse Lung, Hepatocyte, and Ovarian Carcinoma Model Eiji Uchimura, PhD RIKEN Cell Bank |
|
| 1:45 pm-2:00 pm | Vaccine-Based
Therapy Directed Against a Self Antigen (CEA) Demonstrates Anti-Tumor
Activity of Spontaneous Colorectal Tumors in the Absence of Autoimmuntiy
In CEA.Tg/ MIN Mice Hasan E. Zeytin, MD PhD National Cancer Institute, NIH |
|
| 2:00 pm-2:15 pm | Induction
of IFN-G Producing Cells Recognising Ep-CAM Derived MHC Class I Restricted
Peptides after Immunisation with a Recombinant Ep-CAM Protein or a
Human Anti-Idiotypic Antibody Mimicking Ep-CAM Szilvia Mosolits, MD Cancer Center Karolinska |
|
| 2:15 pm-2:30 pm | Peptide
Targeting of Interleukin-12 to Neovasculature Reduces Its Toxicity Erin B. Dickerson, PhD University of Wisconsin |
|
| 2:30 pm-2:45 pm | Refreshment Break | |
| 2:45 pm-5:00 pm | Concurrent Session 1: Cytokines | |
|
Co-Chairs: Jeffrey A. Sosman,
MD |
||
| 2:45 pm-3:15 pm | Efficient
TH1 Response Depends on Coordinate Action of IL-12, IL-13 and IL-27 Stefan Pflanz, PhD DNAX Research Institute |
|
| 3:15 pm-3:45 pm | DC-Activating
Function of the IL-1 Homologues [IL-1, IL-18, IL-1F7] and NK Cells
in the Development of Antitumor Responses Michael T. Lotze, MD University of Pittsburgh |
|
| 3:45 pm-4:15 pm | Cytokine
Deregulation in Cancer Razelle Kurzrock, MD MD Anderson Cancer Center |
|
| 4:15 pm-4:30 pm | A
3-Arm Randomized Comparison of High and Low Dose Intravenous and Subcutaneous
Interleukin-2 in the Treatment of Metastatic Renal Cancer James C. Yang, MD National Cancer Institute, NIH |
|
| 4:30 pm-4:45 pm | Mechanisms
of Enhanced Antigen-Specific T Cell Response Following Vaccination
with a Novel Peptide-Based Cancer Vaccine and Systemic Interleukin-2 Mohamed Salem, PhD Medical University of South Carolina |
|
| 4:45 pm-5:00 pm | Systemic
Administration of IL-15 Augments the Antigen-Specific Primary CD8+
T Cell Response Following Vaccination Mark P. Rubinstein Medical University of South Carolina |
|
| 2:45 pm-5:00 pm | Concurrent Session 2: 2001 Immune Monitoring Workshop Follow-Up | |
|
Co-Chairs: Ulrich Keilholz,
MD |
||
| 2:45 pm-3:15 pm | Mary
L. (Nora) Disis, MD University of Washington |
|
| 3:15 pm-3:45 pm | HLA
Antigen Abnormalities in Malignant Cells Soldano Ferrone, MD, PhD Roswell Park Cancer Institute |
|
| 3:45 pm-4:15 pm |
Lessons from Immune Monitoring of Clinical Trials Carmen Scheibenbogen, MD University Hospital Benjamin Franklin |
|
| 4:15 pm-4:30 pm | Quantitating
Antigen-Specific T Cell Responses in Peripheral Blood- A Comparison
of Peptide MHC Tetramer, ELISpot and Intracellular Cytokine Analysis Timothy Clay, PhD Duke University Medical Center |
|
| 4:30 pm-4:45 pm | Migratory
Pattern of Cytotoxic T Cells: Melanoma-Reactive CD8+ Effector T cells
Express CXCR4 and Accumulate in Bone Marrow Anne Letsch, MD University Hospital Benjamin Franklin |
|
| 4:45 pm-5:00 pm | Hallmarks
of Effective Immunity: Avidity and Homing of Tumor-Specific T-Cells Markus Maeurer, MD University of Mainz |
|
| 5:00 pm-6:30 pm |
Presidential
Reception
Announcement of Presidential Award Winner |
|